title: Effects of platelets and platelet-derived material on the activated partial thromboplastin time (Cephotest) coagulation test.
abstract: OBJECTIVE
  The Cephotest is an activated partial thromboplastin time (APTT) test used to measure the activity of the intrinsic pathway of coagulation. To perform this test, blood is usually centrifuged to obtain plasma that is almost without erythrocytes and leucocytes and with only a minimal amount of platelets.
  
  
  METHODS
  In the present experiments blood was centrifuged at different speeds to produce either platelet-poor plasma (PPP) or platelet-rich plasma (PRP). PPP and PRP obtained from the same whole blood samples from each of several persons were tested in pairs using the standard Cephotest reagent to observe the consequences of Cephotest being performed on plasma containing platelets. The same procedure was used with a Cephotest reagent with a reduced concentration of phosphatidylserine. In succeeding experiments the PRP was preincubated with SFLLRN or Ca-ionophore to activate the platelets, a procedure also known to produce platelet-derived microparticles. PPP and PRP were compared by thrombin time and reptilase time tests to find out at which stage platelets might influence the Cephotest.
  
  
  RESULTS
  The results showed that the platelets did influence Cephotest when using both the regular reagent and the phospholipid-reduced agent. When using the regular reagent, PRP showed a tendency towards a longer APTT than PPP. It is suggested that this was caused by platelets consuming some of the first traces of thrombin generated.
  
  
  CONCLUSIONS
  When using the phospholipid-reduced reagent, PRP showed a shorter APTT than PPP, probably because the platelets contributed phosphatidylserine to the system. When the platelets were activated before testing, their effects on the tests were increased. Microparticles that formed during platelet activation may have contributed to these effects.
authors.affiliation: Research Institute for Internal Medicine, University of Oslo, Rikshospitalet, Norway.
authors.forename: E E
authors.initials: EE
authors.lastname: Mendelsohn
authors.forename: N O
authors.initials: NO
authors.lastname: Solum
authors.forename: F
authors.initials: F
authors.lastname: Brosstad
mesh_terms: D001777:Blood Coagulation; D001792:Blood Platelets; D001798:Blood Proteins; D002118:Calcium / Q000378:metabolism; D005174:Factor XII / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007476:Ionophores; D010314:Partial Thromboplastin Time / Q000379:methods* / Q000592:standards*; D010316:Particle Size; D010446:Peptide Fragments / Q000378:metabolism; D010714:Phosphatidylethanolamines; D010718:Phosphatidylserines; D011498:Protein Precursors / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D015203:Reproducibility of Results; D012997:Solvents; D013917:Thrombin / Q000378:metabolism; D013918:Thrombin Time
chemical_list: D001798:Blood Proteins; D007476:Ionophores; D010446:Peptide Fragments; D010714:Phosphatidylethanolamines; D010718:Phosphatidylserines; D011498:Protein Precursors; D012997:Solvents; C029733:prothrombin fragment 1; C044183:prothrombin fragment 2; D011516:Prothrombin; D005174:Factor XII; D013917:Thrombin; D002118:Calcium